Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation
Authors:
- Richard C CookRCRichard C Cook
- Joseph M ConnorsJCJoseph M Connors
- Randy D GascoyneRGRandy D Gascoyne
- Guy FradetGFGuy Fradet
- Robert D LevyRLRobert D Levy
- 1 November 1999
- journal article
- Published by Elsevier in The Lancet
- Vol. 354 (9191) , 1698-1699
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Anti–B-Cell Monoclonal Antibody Treatment of Severe Posttransplant B-Lymphoproliferative Disorder: Prognostic Factors and Long-Term OutcomeBlood, 1998
- Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disordersThe Lancet, 1998
- Complete Sustained Response of a Refractory, Post-Transplantation, Large B-Cell Lymphoma to an Anti-CD22 ImmunotoxinAnnals of Internal Medicine, 1997
- REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPYThe Lancet, 1984